6-[[3-[(1S)-2-甲氧基-1-甲基乙氧基]-5-[(1S)-1-甲基-2-苯基乙氧基]苯甲酰基]氨基-3-吡啶羧酸 | 851884-87-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-[[3-[(1S)-2-甲氧基-1-甲基乙氧基]-5-[(1S)-1-甲基-2-苯基乙氧基]苯甲酰基]氨基-3-吡啶羧酸
• 中文别名: 6-[[3-[(1S)-2-甲氧基-1-甲基乙氧基]-5-[(1s)-1-甲基-2-苯基乙氧基]苯甲酰基]氨基]-3-吡啶羧酸
• 英文名称: GKA50
• 英文别名: 6-[[3-[(2S)-1-methoxypropan-2-yl]oxy-5-[(2S)-1-phenylpropan-2-yl]oxybenzoyl]amino]pyridine-3-carboxylic acid
• CAS: 851884-87-2
• 化学式: C₂₆H₂₈N₂O₆
• 分子量: 464.518
• InChiKey: OCBMECSFDVUYQN-ROUUACIJSA-N

物化性质

• 沸点：
  607.0±55.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶15mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  7

制备方法与用途

生物活性

GKA50 是一种有效的葡萄糖激酶 (glucokinase) 激活剂 (EC50=33 nM)。GKA50 刺激小鼠胰岛和 MIN6 细胞分泌胰岛素。GKA50 对高脂高脂脂肪雌性大鼠有显著的降糖作用。

体外研究

GKA50 (0.01-100 μM; 24 hours) enhances INS-1 cell proliferation with EC ₅₀ values ranging from 1 to 2 μM.
GKA50 (1.2 μM+40 μM glucose; 2-4 days) treatment reduces apoptosis induced by chronic high glucose in INS-1 cells.
GKA50 activates human glucokinase enzymatic activity with an EC ₅₀ of 0.022 μM. GKA50 stimulates insulin secretion in the pancreatic insulinoma cell line, INS-1, with an EC ₅₀ of 0.065 μM. GKA50 reduces chronic-high-glucose-induced apoptosis via modulation of glucokinase and apoptotic protein BAD.

Cell Proliferation Assay

Cell Line:	INS-1 cells (starved overnight with 3 μM glucose)
Concentration:	0.01-100 μM
Incubation Time:	24 hours
Result:	Stimulated cell proliferation in a dose-dependent manner, with EC 50 values ranging from 1 to 2 μM.

体内研究

GKA50 (1-30 mg/kg; p.o.) gives significant glucose lowering in an oral glucose tolerance test.

Animal Model:	High-fat-fed obese female Zucker (fa/fa) rats
Dosage:	1, 3, 10, 30 mg/kg
Administration:	Oral administration
Result:	Significant percentage glucose lowering.

反应信息

• 作为产物：
  描述：

  methyl 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylate 在 甲醇 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 6-[[3-[(1S)-2-甲氧基-1-甲基乙氧基]-5-[(1S)-1-甲基-2-苯基乙氧基]苯甲酰基]氨基-3-吡啶羧酸
  参考文献：
  名称：

  [EN] PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS
  [FR] DERIVES D'ACIDES CARBOXYLIQUE DE PYRIDINE EN TANT QUE MODULATEURS DE LA GLUCOKINASE

  摘要：

  式(I)的化合物：其中：A为苯基或5-或6-成员杂环芳基环，可选择地取代；R1和R2从氢和甲基中选取；条件是R1和R2中至少有一个为甲基；或其盐、前药或溶剂化合物。描述了它们作为GLK激活剂的用途，含有它们的药物组合物以及它们的制备方法。

  公开号：

  WO2005044801A1

文献信息

• PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS
  申请人：Wacker Dean A.

  公开号：US20090023702A1

  公开（公告）日：2009-01-22

  Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.

  提供了一些新的化合物，它们是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR 119 G蛋白偶联受体调节剂疗法的疾病方面非常有用。这些新的化合物具有结构式I或结构式IA。
• PYRIMIDINYLPIPERIDINYLOXYPYRIDINONE ANALOGUES AS GPR119 MODULATORS
  申请人：Wacker Dean

  公开号：US20110251221A1

  公开（公告）日：2011-10-13

  Novel compounds of structure Formula I: or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein n 1 , R 1 , R 2 , R 3 and R 4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  结构式I的新化合物：或其对映体、非对映体异构体或药用可接受盐，其中n1、R1、R2、R3和R4在此处定义，这些化合物是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，该公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。
• PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS
  申请人：Caulkett William Rodney Peter

  公开号：US20070078168A1

  公开（公告）日：2007-04-05

  A compound of Formula (I): wherein: A is phenyl or a 5- or 6-membered heteroaryl ring, optionally substituted; R 1 and R 2 are selected from hydrogen and methyl; with the proviso that at least one of R 1 and R 2 is methyl; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  公式（I）的化合物：其中：A为苯基或5或6成员的杂环芳基环，可选择取代；R1和R2为氢或甲基；但至少有一个R1和R2为甲基；或其盐、前药或溶剂化物。描述了它们作为GLK激活剂的用途，包含它们的制药组合物以及它们的制备方法。
• [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS
  申请人：Fevig John M.

  公开号：US20090018055A1

  公开（公告）日：2009-01-15

  Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n 2 , n 3 , n 4 , A, B, D, E, G, J, Y, R 1 and R 2 are defined herein.

  提供了一种新型化合物，它们是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面非常有用。这些新型化合物的结构为：或其立体异构体、前药或药物可接受的盐，其中n2、n3、n4、A、B、D、E、G、J、Y、R1和R2在此定义。
• METHOD FOR MODULATING GPR119 G PROTEIN-COUPLED RECEPTOR AND SELECTED COMPOUNDS
  申请人：Wacker Dean A.

  公开号：US20090042919A1

  公开（公告）日：2009-02-12

  A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.

  一种调节GPR119 G蛋白偶联受体活性的方法，包括向需要治疗的哺乳动物患者施用至少一种公式I或公式IA化合物的治疗有效量，以及可选的其他治疗剂。